

# At 14-Days Does the Janssen Vaccine Prevent COVID?

## The EUA Document Results Comparing Vaccinated with Non-Vaccinated Individuals

14 Days after the Injection there were fewer cases of COVID & The Difference in the number of cases was statistically significant.  $p \leq 0.05$

Table 14. Vaccine Efficacy of First Occurrence of Moderate to Severe/Critical COVID-19 Including Non-centrally Confirmed Cases, With Onset at Least 14 or at Least 28 Days After Vaccination, by Baseline SARS-CoV-2 Status<sup>a</sup>, Per Protocol Set

Baseline SARS-CoV-2 Serostatus <sup>a</sup>	Onset at Least 14 Days		Onset at Least 28 Days		VE% <sup>b</sup> (95% CI)	VE% <sup>b</sup> (95% CI)
	Ad26.COV2.S Cases (N)	Placebo Cases (N)	Ad26.COV2.S Cases (N)	Placebo Cases (N)		
Regardless of baseline SARS-CoV-2 status	176 (21636)	513 (21574)	114 (21424)	326 (21199)	66.1% (59.7, 71.6)	65.5% (57.2, 72.4)
Positive	3 (2122)	4 (2030)	1 (2118)	2 (2021)	28.5% (-322.8, 89.5)	65.5% (57.2, 72.4)
Negative	173 (19514)	509 (19544)	113 (19306)	324 (19178)	66.3% (59.9, 71.8)	65.5% (57.2, 72.4)

Source: Sponsor tables GEFPE07A, GEFPE07C

N=Total number of participants at risk per category

<sup>a</sup> Based on serological test at baseline

<sup>b</sup> If fewer than 6 cases are observed for an endpoint then the VE is not shown

N.B. On page 6 of the EUA,



	Observed	Expected	Marginal Row Totals
Johnson & Johnson	21460 (21290.75) [1.35]	21121 (21290.25) [1.35]	42581
Nothing	21061 (21230.25) [1.35]	21399 (21229.75) [1.35]	42460
Marginal Column Totals	42521	42520	85041 (Grand Total)

The chi-square statistic is 5.3895. The p-value is .020258. Significant at  $p < .05$

The chi-square statistic with Yates correction is 5.3577. The p-value is .020631. Significant at  $p < .05$ .

$$\text{Absolute Risk Reduction (ARR)} = 2.38\% \text{ minus } 0.81\% = 1.57\%$$